InvestWiser

Abera Bioscience AB

ABERANasdaq StockholmHealthcareMarket value 156 m SEK
7.28SEK +0.3%
last day · Price as of 20 November 2026

The answer first

Does Abera Bioscience beat the market?

Yes, Abera Bioscience has beaten the market over the last year.

Abera Bioscience+23.4%Stockholm (OMXSGI)+13.6%
  • The ranking · Quality, value and trend combined

    Better than 35% of Nordic stocks

    • Quality66
    • Value2
    • Trend65

    No. 92 of 195 in healthcare

Max for seven days

Follow Abera Bioscience with Aurora

Aurora lets you know at the next report. No card.

Both with dividends. Figures as of 20 November 2026. General analysis, not personal advice.

Follow your thesis

Follow your thesis on Abera Bioscience

From today, at a price of 7.28 SEK. Write why you follow Abera Bioscience, and choose what Aurora should tell you about.

What should Aurora follow?

Free, no card. The mission is ready when your account is.

Aurora tells you that something happened. What you do is your choice.

Ask Aurora about Abera Bioscience

Your first answer is free, no account needed.

Do you own Abera Bioscience, or are you thinking about it?

See it next to the rest of your portfolio, or build your first one with Abera Bioscience and a few more. Free, no card.

Past year against the exchange and Super Stock
Abera Bioscience+23.4%Stockholm (OMXSGI)+13.6%Super Stock+45.3%
19 November 202520 November 2026
All start at 0 % a year ago, with dividends. Super Stock is our model portfolio: the 20 highest-ranked Nordic stocks on quality, value and trend.

In short

  • Abera Bioscience has risen 23.4% over the past year, including dividends.
  • Overall, Abera Bioscience ranks better than 35% of Nordic stocks on quality, value and trend.
  • The largest fall over the past three years was 86.6%. The price is 75.7% below its peak now.

Quality, value and trend

Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.

35

Quality, value and trend together. Better than 35% of Nordic stocks.

No. 92 of 195 in healthcare

Quality66
The company · Fundamentals: the accounts

Medium An average company: the accounts are neither especially strong nor weak.

No. 96 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50

  • Debt to equityBorrowings divided by equity–
  • Asset turnoverSales divided by everything the company owns0.00
  • Return on equityProfit divided by equity−117.1%
  • Cash conversionOperating cash flow divided by profit–

The ranking is built on equity ratio, ROA and how steadily profit grows.

Value2
The price · Valuation: the multiples

Low High price: buyers pay a lot today, often because they expect growth.

No. 185 of 197 in healthcareTypical in healthcare: 19Typical in the Nordics: 50

  • P/BPrice divided by equity7.9
  • P/SPrice divided by sales–
  • P/EPrice divided by earningsnegative earnings
  • P/CFPrice divided by operating cash flownegative earnings

The ranking is built on P/E, P/B and P/S.

Trend65
The share price · Technical: the price trend

Medium The share price has moved about like most stocks over the last year.

No. 57 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50

  • 3 months−11.0%
  • 6 months+6.4%
  • 9 months+14.6%
  • 12 months+23.4%

The ranking is built on 3, 6 and 12–1 months.

Return and risk

1 month
−3.2%
3 years, per year
+15.0%
5 years, per year
−16.7%
Year to date
+7.1%
Largest fall, 3 years
−86.6%
From a peak to the bottom
From the peak now
−75.7%
How far the price is from the peak
Volatility, 1 year
60.6%
How much the price swings over a year
Beta, 1 year
0.21
How much the price moves when the market moves

Return with dividends reinvested.

About Abera Bioscience

Abera Bioscience AB is a company in healthcare, listed on Nasdaq Stockholm. By market value, Abera Bioscience is number 76 of 137 companies in healthcare on Nasdaq Stockholm. Abera Bioscience has not paid a dividend in the past twelve months. Of the three measures in the ranking, Abera Bioscience is strongest on quality, better than 66% of Nordic stocks. The share trades in SEK. It has around 5 employees.

Abera Bioscience AB (publ), a platform and vaccine development company, develops vaccines based on its proprietary and patented platform in Sweden and internationally. The company's development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine. The company also develops projects in Flu, Diarrhea Chlamydia, ETEC, Covid-19, and Tuberculosis. The company was incorporated in 2012 and is headquartered in Uppsala, Sweden.

See the full analysis of Abera Bioscience.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

Free forever · No card

Other healthcare stocks on Nasdaq Stockholm

Explore the stock market